Lancet Oncol 21 (4): 519-530, 2020.[PUBMED Abstract] Verma S, Miles D, Gianni L, et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer.
N Engl J Med 367 (19): 1783-91, 2012.[PUBMED Abstract] Di√©ras V, Miles D, Verma S, et al.: Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol 18 (6): 732-742, 2017.[PUBMED Abstract] Hurvitz SA, Dirix L, Kocsis J, et al.: Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.